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sobre los intervalos posteriores al tratamiento que comparan 
las diferentes duraciones del tratamiento, la duración recomen-
dada del tratamiento sería de 7 días16. Una limitación es que 
estos estudios fueron realizados principalmente por compañías 
farmacéuticas. También en medicina humana, las directrices su-
gieren un mínimo de 5 días de tratamiento y un estado afebril de 
48 a 72 horas antes de la interrupción de la terapia17. Reducir 
la duración del tratamiento sigue siendo un reto en la práctica, 
muy probablemente porque los médicos y veterinarios tienen 
una falsa sensación de seguridad con tratamientos más largos. 
Sin embargo, la hipótesis sería que los tratamientos antibióticos 
acortados reducen la selección de la resistencia a los antimicro-
bianos, ahorran costes, evitan los efectos adversos relaciona-
dos con los antimicrobianos y aseguran un mejor cumplimiento 
del tratamiento. En la charla se abordarán las posibilidades de 
evaluación ecográfica de la curación y las posibilidades de redu-
cir e individualizar la terapia antimicrobiana. 
En conclusión, la OMS proporciona información clara sobre los 
pasos a seguir en el proceso de toma de decisiones sobre los 
antimicrobianos, lo que puede ayudar a los profesionales en su 
trabajo diario. Claramente, se requieren muchas mejoras en la 
detección, diagnóstico y seguimiento de la terapia, antes de que 
los veterinarios se sientan lo suficientemente seguros como 
para dejar a los animales sin evidencia de neumonía bacteriana 
sin tratar. 
Figura 1. Descripción general de la terminología y las etapas 
del proceso de toma de decisiones sobre los antimicrobianos 
en los animales
Bibliografía
1. En la version inglesa
ENGLISH VERSION  
RATIONALIZING ANTIMICROBIAL TREATMENT FOR RESPIRA-
TORY INFECTIONS: STEPS TO TAKE TODAY AND TOMORROW
B. Pardon
Department of Large Animal Internal Medicine, Faculty of Vet-
erinary Medicine, Ghent University, Salisburylaan 133, 9820 
Merelbeke, Belgium
Respiratory tract infections (RTIs) are the most common infec-
tions worldwide. They are a source of significant morbidity, 
mortality and a considerable economic burden to modern cattle 
farming1. A particularly urgent issue is that they account for over 
65% of the antimicrobial use in intensive calf rearing systems2. 
The European Union commissions a significant reduction in an-
timicrobial use in food animals in the following years, as part of 
a more sustainable production system3. With enlarging groups 
of animals to be managed by the same person, metaphylactic 
therapies (group treatments) have become increasingly popular 
over the last 20 years. From the perspective of human medicine 
or the public opinion, several aspects like treating in contact 
animals with mild signs and the almost standard use of antimi-
crobials in cases of primary viral origin are highly controversial 
and perceived as signs of irresponsible antimicrobial use. Ad-
ditionally, the recent findings that about 40% of calves housed 
in herds not reporting any issues with respiratory diseases, have 
pneumonic lesions on lung ultrasonography (so-called subclini-
cal pneumonia) complicate things, pointing to a possible welfare 
issue by not treating these animals (van Leenen et al., 2018). 
Looking at a recent meta-analysis of metaphylaxis for bovine 
respiratory disease (BRD), at first sight moderate (but highly 
variable) reductions in respiratory morbidity are shown4. How-
ever, the number needed to treat at a common attack rate (= 
percentage of ill animals at the point of initiation of a group 
treatment) of 10%, ranges between 10 and 100. This means that 
many animals need to receive the treatment, before one would 
be saved, numbers unlikely to be accepted by consumers. Also, 
the highest absolute risk reductions have been shown in ran-
domized clinical trials, with a follow up period of less than 30 
days, whereas longer trials show no effect anymore. The results 
of this meta-analysis clearly raise doubt whether metaphylaxis 
and treatment at the earliest signs are the best approach to 
manage respiratory infections in cattle. To tackle antimicrobial 
mass medication to control respiratory infections, a shift from 
group to individualized treatments will be essential. 
In this talk, an overview of general principles to rationalize an-
timicrobial use based on recommendations of the world health 
organization directed to human medicine is provided. The ex-
ample of bovine respiratory disease (BRD) is elaborated.
Rational antimicrobial therapy
Rational use of medicines requires that animals/patients re-
ceive medications appropriate to their clinical needs, in doses 
that meet their own individual requirements, for an adequate 
period of time, and at the lowest cost to them and their commu-
nity (WHO, 2019). Prudent use is defined as use which benefits 
the patient while at the same time minimizing the probability of 
adverse effects for the individual and the emergence or spread 
of antimicrobial resistance. In fact the terminology ‘prudent use’ 
is used interchangeably with judicious, rational, adequate, cor-
rect or optimal antimicrobial use. In a farm animal context ra-
tional antimicrobial therapy can be freely translated to optimum 
therapy for the animal (welfare aspect), farm economics (pro-
ductivity aspect) and public/environmental health (resistance 
selection). Basic concepts for a rational use are: (1) use of ef-
fective antimicrobials in the first, empiric treatment; (2) use the 
narrowest spectrum possible, targeting the pathogen but with 
minimal collateral damage to the resident flora; (3) include mi-
crobiological testing as much as possible; (4) avoid oral therapy 
(order of resistance selection: oral therapy >> parenteral ther-
apy > local therapy); (5) individual treatments (abandon group 
treatments) and (6) do not use combinations of antimicrobials 
with an unproven synergism. It is clear that the largest prog-
ress can be made with a switch from a group therapy approach 
towards individual therapy. Likely, a rational view point would 
be only to treat animals with bacterial pneumonia. Off course, 
veterinarians can immediately raise several practical issues for 
this approach, in particular how to reliably identify animals with 
a bacterial pneumonia. 
The antimicrobial decision making process
Worldwide, thousands of veterinarians daily take numerous 
decisions to initiate antimicrobial therapy. Potentially not all of 
them realize it sufficiently, but a whole reasoning process pro-
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in the antimicrobial decision making process is provided. The 
first step is detecting the ill animal. The initial evaluation of 
every case consists of clinical assessment, a diagnostic work 
up, therapeutic decision and ‘owner’ education. WHO recom-
mends ‘an informed choice for an optimal antimicrobial’, which 
can be selected by taking 5 reasoning steps: (1) What is the 
severity of the infection? ; (2) What is the most likely source and 
pathogen?; (3) How likely is it that the infection is caused by 
resistant bacteria?; (4) Are any patient factors to be taken into 
account?; (5) Do I need to sample and request culturing before 
initiating therapy?. Thereafter, an empiric therapy is started. 
An empiric therapy is defined as a therapy which is not sup-
ported by any microbiological analysis. The veterinarian basis 
his selection of an antimicrobial on his own experience (most 
likely bacteria for this presentation in this farm), own farm data 
and national data. When results of microbiological testing be-
come available an evaluation should be done. This process has 
4 steps: (1) review microbiological data; (2) assess spectrum of 
empiric therapy, (3) check for adverse effects and (4) evaluate 
route and duration of therapy. When antimicrobial susceptibil-
ity test results become available, the veterinarian can evaluate 
whether his empiric therapy can be judged as appropriate (= 
bacteria are susceptible to the selected drug) or inappropriate 
(= bacteria are resistant to the selected drug). An antimicrobial 
treatment which is supported by an antimicrobial susceptibility 
test is referred to as a definitive antimicrobial therapy. For many 
reasons, but especially when dealing with group treatments, 
veterinarians will need to base their antimicrobial regimens on 
susceptibility testing of representative isolates from the group. 
Advances in detection of animals with respiratory tract infection
Enlarging group sizes make detection of ill animals more dif-
ficult, especially when relatively the number of surveilling staff 
has decreased. In many countries, an increasing number of re-
spiratory tract infection diagnoses and treatments are made by 
producers. A meta-analysis using Bayesian inference showed 
that the overall sensitivity (Se) and specificity (Sp) or producer 
diagnosis in feedlot systems reached 27% (12-65) and 92% (72-
98)5. However, a good screening test needs a high Se, because 
false positive cases can still be excluded by the confirmation 
test after which the case will be finally diagnosed. In fact, many 
producers and veterinarians already apply the screening test- 
confirmation test principle, as they pull animals from groups 
based on signs like depression, and confirm disease in these 
animals by taking temperature. However, a danger of this se-
rial testing approach is that Sp is increased, whereas the main 
interest is in a high Se, in order not to miss an ill animal. Veteri-
narians especially use lung auscultation as a confirmation test, 
but both mean diagnostic accuracy as interrater agreement are 
poor (Pardon et al., 2016). To date lung ultrasonography has the 
highest Se and Sp of all tests evaluated for BRD, with much bet-
ter interrater agreement6,7. Parallel testing (looking at multiple 
signs at once in all animals) and the use of lung ultrasonography 
also for screening purposes, are time consuming, but possibly 
the best options, while awaiting validation of newer technolo-
gies.
A lot is expected from these new technology to automatically 
detect animals requiring attention. Interesting systems, already 
evaluated, include automatic temperature registration, cough 
detection and movement (pedometers and infra-red8). A promi-
nent issue in this field is that there is no gold standard refer-
ence test for bacterial pneumonia, and that most studies have 
worked with the terminology of bovine respiratory disease, not 
distinguishing mild upper respiratory tract infections from life-
threatening pneumonia or subclinical lung consolidations on 
ultrasound. One approach are Bayesian latent-class models, 
which do not require a gold standard. Available work shows that 
in feedlot conditions movement detection reaches a sensitivity 
(Se) of 81.3% (55.5-95.8) and specificity (Sp) of 92.9% (88.2-
96.9), much better than visual producer diagnosis (Se= 64.5 
(57.9-70.8) and Sp= 69.1% (66.3-71.8))8.  
Advances in microbiological diagnosis and rapid susceptibility 
testing
To date, in the vast majority, antimicrobial therapy remains em-
piric, and no further steps for a microbiological diagnosis are 
taken. This situation is no different from human medicine, but 
becomes a lot more delicate if also decisions for group treat-
ments are taken in such a way. It is outside the scope of this 
article to go into great detail on the advantages and disadvan-
tages of the different sampling techniques for the respiratory 
tract in cattle. A deep nasopharyngeal swab, a non-endoscopic 
broncho-alveolar lavage (nBAL) and transtracheal wash/as-
pirate (TTA) are most accessible, complying with the need to 
sample multiple animals in a limited timeframe at low cost 9,10. 
From these samples bacteria can be cultivated and antimicro-
bial susceptibility tests performed. The main issue to overcome 
is the time between sampling and availability of an antibiogram. 
For fastidious growers like Pasteurellaceae, a disk diffusion an-
tibiogram can be obtained as early as 48h after sample arrival 
in the laboratory, but on average it will take 4-5 days. For Myco-
plasma bovis, standard identification procedures alone already 
take 6-7 days. Using the MBT-ASTRA procedure in MALDITOF 
mass spectrometry, susceptibility testing for oxytetracycline in 
Pasteurella multocida was done as fast as within 3h, starting 
from a purified colony. This technique had a Se of 95.7% (89.8-
100) and Sp of 100% (100-100) compared to the reference 
test11. Also direct detection of the pathogens in broncho-alve-
olar lavage fluid (BALf) is likely possible, making the final target 
of pathogen identification and susceptibility testing within the 
day of sampling possible at comparable cost as standard culture 
and disc diffusion testing.  
Precision medicine to reduce antimicrobial exposure
Not only limiting the number of animals receiving antimicrobial 
therapy, but within a single animal also limiting exposure of the 
resident flora to antimicrobial selection pressure is essential. 
Assuring correct dosing by weighing animals at treatment initia-
tion will already result in better therapy, as the majority of paren-
terally administered antimicrobials are overdosed, whereas oral 
antimicrobials are often underdosed12. Especially with concen-
tration dependent antimicrobials, like fluoroquinolones, optimal 
dosing strategies aiming at limiting development of antimicro-
bial resistance by dosing above the mutant prevention concen-
tration have been explored13. Similarly, these studies show that 
the required treatment length, dosage and efficacy depend on 
the time of therapy initiation in the disease process14. Also, the 
rapid elimination of these drugs mitigated long term impacts on 
fecal Escherichia coli resistance15. In many situations, clinical 
cure is the evaluation criterion. When using antimicrobials re-
quiring a daily dosing interval, this will typically be evaluated at a 
post-treatment interval of 1 day, prolonging treatment with one 
day when judged not cured16.  Off course, evaluation of clinical 
cure is likely highly suggestive and prone to a higher interra-
ter variability. When using long acting products, the likely mo-
ment to decide on prolongation or cessation of therapy would 
be after the registered treatment length of the specific product 
has passed.  Based on available post treatment interval studies 
comparing different treatment lengths, the recommended treat-
ment length would be 7 days16. A limitation is that these studies 
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medicine, guidelines suggest a minimum of 5 days of treatment, 
and an afebrile state for 48 to 72 hours before discontinuation 
of therapy17. Reducing treatment duration remains challenging 
in practice, most likely because physicians and veterinarians 
feel a false sense of security with longer treatments. However, 
the hypothesis would be that shortened antibiotic treatments 
reduce antimicrobial resistance selection, save costs, avoid ad-
verse effects related to the antimicrobial and assure a better 
therapy compliance. In the talk we will come to possibilities of 
ultrasonographic evaluation of cure and possibilities to reduce 
and individualize antimicrobial therapy. 
In conclusion, the WHO provides clear information on steps to 
take in the antimicrobial decision making process, which can aid 
practitioners in their daily work. Clearly, many improvements in 
detection, diagnostics and therapy follow up are required, be-
fore veterinarians will feel safe enough to leave animals not evi-
denced as bacterial pneumonia untreated. 
Figure 1. Overview of terminology and steps in the process of 
antimicrobial decision making in animals
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